Iomab-B + Conventional Care
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Trial Timeline
Jun 1, 2016 → Dec 1, 2026
NCT ID
NCT02665065About Iomab-B + Conventional Care
Iomab-B + Conventional Care is a phase 3 stage product being developed by Actinium Pharmaceuticals for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT02665065. Target conditions include Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02665065 | Phase 3 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia